Literature DB >> 12918577

Extracorporeal membrane oxygenation for chickenpox pneumonia: a single institution's experience.

Ralph W White1, Giles J Peek, David R Jenkins, Hilliary M Killer, Richard K Firmin.   

Abstract

The experience of extracorporeal membrane oxygenation (ECMO) use for severe chickenpox pneumonia was reviewed. Case notes of all patients treated with ECMO for this disease between 1992 and 1997 were reviewed. Of 405 patients referred for ECMO during this period, the diagnosis was chickenpox pneumonia in 14 (3.5%); all 14 were treated with ECMO. The median age of patients was 32.5 years (range 5 to 61 years). The median duration of extracorporeal support was 164 hours (range 45 to 652). Ten of 14 patients (71%) required hemofiltration. Overall survival of patients supported with ECMO was 57% (8 of 14). Deaths were caused by sepsis (5 patients, source identified in 4) and multiorgan failure (1 patient). Pneumonia as a complication of chickenpox can rapidly become severe and life threatening. Extracorporeal respiratory support may be helpful in patients refractory to conventional ventilation.

Entities:  

Mesh:

Year:  2003        PMID: 12918577

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  2 in total

1.  Extending the limits of extracorporeal membrane oxygenation: lung rest for a child with non-specific interstitial pneumonia.

Authors:  Iain Macintosh; Warwick W Butt; Colin F Robertson; Derek Best; Lara S Shekerdemian
Journal:  Intensive Care Med       Date:  2005-04-01       Impact factor: 17.440

2.  Varicella associated acute respiratory distress syndrome in an adult patient: an example for extracorporeal respiratory support in Brazilian endemic diseases.

Authors:  Marcela da Silva Mendes; Ho Yeh-Li; Thiago Gomes Romano; Edzangela Vasconcelos Santos; Adriana Sayuri Hirota; Bruna Mitiyo Kono; Marilia Francesconi Felicio; Marcelo Park
Journal:  Rev Bras Ter Intensiva       Date:  2014 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.